Skip to main content
. 2022 Dec 1;13:1003975. doi: 10.3389/fimmu.2022.1003975

Figure 3.

Figure 3

JAM-A is dispensable for myeloid cell accumulation in the primary tumor and in the pulmonary metastatic site. (A) JAM-A expression in myeloid cell populations and endothelial cells in LLC tumors of F11r flox/flox LysM-Cre+ mice normalized to F11r flox/flox LysM-Cre- mice. ND = not detected. Day 17 post-engraftment, tumor volume shown in panel (B). (B) LLC (n=16-17) and Py8119-eGFP (n=14-15) tumor growth in F11r flox/flox LysM-Cre- and F11r flox/flox LysM-Cre+ mice. (C) Frequency of indicated myeloid and lymphoid cell populations in LLC tumors (n=9-10). Day 17 post-engraftment, tumor volume is shown in panel (B). (D) Same as (C) in Py8119-eGFP tumors (n=12-13). Day 31 post-engraftment, tumor volume is shown in panel (B). (E) Frequency of monocytes and neutrophils in the lungs of tumor-bearing mice with Py8119-eGFP tumors (n=14-15). Panel E-G: Day 31 post-engraftment. (F) Proportion of mice with eGFP+ metastatic Py8119 cancer cells in the lung detected via flow cytometry. (G) Frequency of eGFP+ metastatic cancer cells in the lungs of Py8119-eGFP tumor-bearing mice (n=14-15). (H–J) Same as (E–G) for LLC-eGFP tumors (n=15). Day 17 post-engraftment. JAM-A expression and cell frequencies were determined using flow cytometry. All graphs show mean and SEM.